NASDAQ$TXG
10X Genomics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
10X Genomics reported Q2 2025 revenue of $172.9 million and net income of $34.5 million.
Revenue grew 13% year-over-year to $172.9 million, driven by $27.8 million in license and royalty revenue from litigation settlements with Vizgen and Bruker. Gross margin expanded to 72% and the company achieved net income of $34.5 million ($0.28 EPS) versus a loss in the prior year. Operating expenses declined due to restructuring and lower legal costs while cash and cash equivalents reached $397.7 million.
- Q2 revenue of $172.9 million included $27.8 million license/royalty from Vizgen and Bruker settlements.
- Net income reached $34.5 million with gross margin expanding to 72%.
- Instruments revenue fell 39% while spatial consumables grew 24%.
- Company announced May 2025 restructuring and subsequent Scale Biosciences acquisition.
Headline financials
Revenue & EPS history
10X Genomics · Revenue · Quarterly
$173M
Revenue by segment
10X Genomics · $310M total across 8 segments · Q2 2025
- Consumables$122M—39.5%
- Chromium Consumables$85.8M—27.7%
- Spatial Consumables$36.4M—11.8%
- License and Royalty$27.8M—9.0%
- Instruments$14.5M—4.7%
- Spatial Instruments$8.77M—2.8%
- Services$8.48M—2.7%
- Chromium Instruments$5.73M—1.8%
Forward guidance
Revenue excluding license/royalty expected to decline sequentially in Q3 2025; gross margin to fluctuate; operating expenses to trend lower for the year.
Tailwinds
- Restructuring actions to reduce costs
- Strong cash position of $447 million
Headwinds
- Instruments revenue continued to decline
- Non-recurring license revenue benefit ends after H1
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+2.1%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+2.0%
Avg return
30 days after
58%
15 / 26 earnings
Positive
+17.3%
Q3 2025
Best reaction
-21.9%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -3.6% | -5.9% | +38.4% | |
| Q4 2025 | +3.5% | +11.8% | +7.3% | |
| Q3 2025 | +17.3% | +28.4% | +36.7% | |
| Q1 2025 | +1.3% | +5.7% | +9.2% | |
| Q4 2024 | -0.5% | +0.6% | -13.8% | |
| Q3 2024 | +4.0% | +3.0% | -2.4% | |
| Q2 2024 | +12.7% | +18.8% | +18.8% | |
| Q1 2024 | -5.2% | -3.2% | -21.1% | |
| Q4 2023 | +0.8% | -1.3% | -24.4% | |
| Q3 2023 | +15.7% | +13.7% | +33.3% | |
| Q2 2023 | -4.5% | -7.7% | -7.9% | |
| Q1 2023 | +5.9% | +5.5% | +5.7% | |
| Q4 2022 | +14.8% | +15.2% | +7.5% | |
| Q3 2022 | +13.0% | +9.5% | +38.1% | |
| Q2 2022 | +5.4% | +13.2% | -24.0% | |
| Q1 2022 | -0.5% | -6.4% | -10.6% | |
| Q4 2021 | -15.0% | -14.4% | -26.7% | |
| Q3 2021 | +12.7% | +7.7% | -14.9% | |
| Q2 2021 | -1.8% | -3.3% | +3.7% | |
| Q1 2021 | -21.9% | -27.1% | -2.6% | |
| Q4 2020 | -3.1% | -7.1% | -7.6% | |
| Q3 2020 | +1.8% | +3.3% | +11.4% | |
| Q2 2020 | +0.6% | +6.0% | +17.1% | |
| Q1 2020 | -0.4% | -6.0% | +3.1% | |
| Q4 2019 | -2.1% | -11.4% | -40.6% | |
| Q3 2019 | +3.1% | +10.3% | +17.3% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro